Why IBD 50's Guardant Health, Up 137% in 2025, Just Rocketed Again
TRENDING: You Don't Have To Dig Far To Cash In On Rare EarthsGuardant Health (GH) stock rocketed Thursday on an impressive beat-and-raise earnings report that included 40% volume growth from its oncology division.That 40% volume growth for oncology tests was a "wow," William Blair analyst Andrew Brackmann said in a report. The company's suite of liquid biopsy tests, including Guardant360, use genomic profiling to determine the drivers of a patient's cancer. This helps doctors select the right, targeted trea ...